Skip to main content
Passa alla visualizzazione normale.

GIUSEPPE BADALAMENTI

Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma

  • Authors: Badalamenti, G; Incorvaia, L; Provenzano, S; Bronte, G; Leto, G; Fulfaro, F; Maltese, G
  • Publication year: 2013
  • Type: Articolo in rivista (Articolo in rivista)
  • Key words: lenograstrim, sarcoma, neutropenia
  • OA Link: http://hdl.handle.net/10447/70003

Abstract

Background: Neutropenia and its complications represent one of the principal dose-limiting toxicity issues in chemotherapeutic regimens for soft tissue sarcoma. Prophylactic granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN). The correct timing of G-CSF administration should be considered in order to optimize the prophylactic treatment. Patients and Methods: Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9. The proportion of patients experiencing FN and G4 neutropenia was considered. Results: A total of 36 patients receiving three cycles of chemotherapy with epirubicin plus ifosfamide were treated. None developed FN; G4 neutropenia was reported in 17% of patients. No treatment delay or dose reduction was required, no antibiotic therapy was administered and no hospitalization occurred. Conclusion: Five-day lenograstim treatment is efficient as prophylaxis of FN for soft tissue sarcoma chemotherapy regimens and allows maintenance of chemotherapy dose intensity.